| Target Price | $35.19 |
| Price | $18.37 |
| Potential |
91.56%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Summit Therapeutics PLC Sponsored ADR 2026 .
The average Summit Therapeutics PLC Sponsored ADR target price is $35.19.
This is
91.56%
register free of charge
$44.10
140.07%
register free of charge
$12.12
34.02%
register free of charge
|
|
| A rating was issued by 22 analysts: 18 Analysts recommend Summit Therapeutics PLC Sponsored ADR to buy, 2 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Summit Therapeutics PLC Sponsored ADR stock has an average upside potential 2026 of
91.56%
register free of charge
|
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wolfe Research |
Locked
➜
Locked
|
Locked | Nov 18 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Oct 22 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Oct 21 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 21 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Oct 20 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Oct 20 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Nov 18 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Oct 22 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Oct 21 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 21 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Oct 20 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Oct 20 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 17 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


